Respiratory disorders and hospitalization rates during the second RSV season in preterm infants who received palivizumab prophylaxis during their first RSV season

Journal of Chemotherapy

Volumn 21, Issue 3, 2009, Pages 302-310

  Fanos, V ^a   Scarcella, A ^b   Puddu, M ^a   Gallini, F ^c   Tuminelli, F ^d   Bragetti, P ^e   Gallina, M R ^f   Quartulli, L ^g   Benincori, N ^h   Citro, G ⁱ   Dalla Via, L ^j   Barera, G ^k   Di Luzio Paparatti, U ^l   Merolla, R ^l   Romano, G V ^l   Guida, G ^l   Silvestri, M ^m   Rossi, Giovanni A ^m  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d Umberto I Hospital   (Italy)

^e Monteluce Polyclinic ^*  (Italy)

^f MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

^g PERRINO HOSPITAL   (Italy)

^h General Surgery Unit GB Grassi Hospital   (Italy)

ⁱ Umberto I Hospital   (Italy)

^j Thiene Hospital   (Italy)

^k VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^l ABBOTT DIAGNOSTICS   (Italy)

^m G GASLINI INSTITUTE   (Italy)

more..

Author keywords

Hospitalization; Palivizumab; Recurrent wheezing; Respiratory syncytial virus; RSV

Indexed keywords

PALIVIZUMAB;

AGE DISTRIBUTION; ANTIBIOTIC THERAPY; ARTICLE; ASTHMA; BRONCHIOLITIS; CONTROLLED STUDY; CROUP; FAMILY HISTORY; FEMALE; FOLLOW UP; GESTATIONAL AGE; HOSPITALIZATION; HUMAN; INFANT; INFECTION PREVENTION; ITALY; LENGTH OF STAY; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PNEUMONIA; PREMATURITY; RECURRENT DISEASE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RISK FACTOR; SEX DIFFERENCE; WHEEZING;

EID: 68349091350     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2009.21.3.302     Document Type: Article

References (24)

1. Kimpen JL, Simoes EA. Respiratory syncytial virus and reactive airway disease. New developments prompt a new review. Am J Respir Crit Care Med 2001; 163 (3 Pt 2): S1.
2. Ogra PL. Respiratory syncytial virus: The virus, the disease and the immune response. Paediatr Respir Rev 2004; 5 (Suppl A): S119-126.
3. Law BJ, Carbonell-Estrany X, Simoes EA. An update on respiratory syncytial virus epidemiology: A developed country perspective. Respir Med 2002; 96 (Suppl B): S1-7. (Pubitemid 39665384)
4. Bont L, Steijn M, Van Aalderen WM, Brus F, Th Draaisma JM, Van Diemen-Steenvoorde RA, et al. Seasonality of long term wheezing following respiratory syncytial virus lower respiratory tract infection. Thorax 2004; 59 (6): 512-516. (Pubitemid 38797525)
5. Henderson J, Hilliard TN, Sherriff A, Stalker D, Al Shammari N, Thomas HM. Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: A longitudinal birth cohort study. Pediatr Allergy Immunol 2005; 16 (5): 386-392.
6. Sigurs N. Epidemiologic and clinical evidence of a respiratory syncytial virus-reactive airway disease link. Am J Respir Crit Care Med 2001; 163 (3 Pt 2): S2-6. (Pubitemid 32336735)
7. Sigurs N, Gustafsson PM, Bjarnason R, Lundberg F, Schmidt S, Sigurbergsson F, et al. Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med 2005; 171 (2): 137-141. (Pubitemid 40105412)
8. Stein RT, Sherrill D, Morgan WJ, Holberg CJ, Halonen M, Taussig LM, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999; 354 (9178): 541-545. (Pubitemid 29381367)
9. Bont L, Steijn M, van Aalderen WM, Kimpen JL. Impact of wheezing after respiratory syncytial virus infection on health-related quality of life. Pediatr Infect Dis J 2004; 23 (5): 414-417. (Pubitemid 38621479)
10. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102 (3 Pt 1): 531-537.
11. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH, Jr., et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003; 143 (4): 532-540.
12. Simoes EA, Groothuis JR, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick LM, et al. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr 2007; 151 (1): 34-42. (Pubitemid 46935179)
13. Medici MC, Arcangeletti MC, Rossi GA, Lanari M, Merolla R, Paparatti UD, et al. Four year incidence of respiratory syncytial virus infection in infants and young children referred to emergency departments for lower respiratory tract diseases in Italy: the "Osservatorio VRS" Study (2000-2004). New Microbiol 2006; 29 (1): 35-43.
14. Shattuck KE, Abu-Ghosh AM, Wildin SR, Landry SH, Smith KE. Respiratory morbidity in three-year-old children born preterm. Neonatal Intens Care 1998; 11 (1): 11-15
15. Societa' Italiana di Neonatologia. Raccomandazioni per la prevenzione della malattia da virus respiratorio sinciziale (RSV). Riv Ital Pediatr 2000; 26 (3): 379-381
16. Ruuskanen O, Ogra PL. Respiratory syncytial virus. Curr Probl Pediatr 1993; 23 (2): 50-79.
17. Campbell A, Pollack P, M. Fredrick L, Groothuis JR. RSV hospitalization rates in preterm children in the season following palivizumab prophylaxis compared to children without palivizumab prophylaxis. Arch Dis Child 2008; 93 (Suppl II): A339-446 [Abstract].
18. Giovannini M, Rossi GA, Merolla R, Arena F, Cutrera R, Dalla Casa P, et al. Respiratory diseases in infants hospitalized during the 1st 2 years of life for viral lower respiratory tract infections: a one-year follow-up. Minerva Pediatr 2003; 55 (2): 149-155.
19. Lanari M, Giovannini M, Giuffrè L, Marini A, Rondini G, Rossi GA, et al. Epidemiological survey on Italian infants hospitalized with lower respiratory tract infections: role of Respiratory Syncytial Virus. Pediatr Pulmonol 2002; 33: 458-464
20. Puddu M, Fanos V. Respiratory syncytial virus infection and recurrent wheezing: what next? J Chemother 2007; 19 (Suppl 2): 8-11.
21. Carbonell-Estrany X, Quero J. Hospitalization rates for respiratory syncytial virus infection in premature infants bom during two consecutive seasons. Pediatr Infect Dis J 2001; 20 (9): 874-879. (Pubitemid 32880323)
22. Carbonell-Estrany X, Quero J, Bustos G, Cotero A, Domenech E, Figueras-Aloy J, et al. Rehospitalization because of respiratory syncytial virus infection in premature infants younger than 33 weeks of gestation: A prospective study. IRIS Study Group. Pediatr Infect Dis J 2000; 19 (7): 592-597. (Pubitemid 30469763)
23. Underwood MA, Danielsen B, Gilbert WM. Cost, causes and rates of rehospitalization of preterm infants. J Perinatol 2007; 27 (10): 614-619. (Pubitemid 47491471)
24. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, Grijalva CG, Zhu Y, Szilagyi P. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009; 360 (6): 588-598